The skin as a barrier and immune organ is exposed to omnipresent environmental challenges such as irradiation or chemical and biologic hazards. Neuropeptides released from cutaneous nerves or skin and immune cells in response to noxious stimuli are mandatory for a fine-tuned regulation of cutaneous immune responses and tissue maintenance and repair. They initialize host immune responses, but are equally important for counter regulation of proinflammatory events. Interaction of the nervous and immune systems occurs both locally -at the level of neurogenic inflammation and immunocyte activation -and centrally -by controlling inflammatory pathways such as mononuclear activation or lymphocyte cytokine secretion. Consequently, a deregulated neurogenic immune control results in disease manifestation and frequently accompanies chronic development of cutaneous disorders. The current understanding, therapeutic options, and open questions of the role that neuropeptides such as substance P, calcitonin gene-related peptide, vasoactive intestinal peptide/pituitary adenylate cyclaseactivating polypeptide, neuropeptide Y, or others play in these events are discussed. Progress in this field will likely result in novel therapies for the management of diseases characterized by deregulated inflammation, tissue remodeling, angiogenesis, and neoplasm.
Introduction
The skin is one of the principal sites of host interaction with the environment where various types of stimuli can be received and processed by the peripheral and central nervous system. Neuropeptides are known to play key roles in mediating this interaction ever since members of this evolutionarily ancient, highly conserved, and very diverse class of signaling molecules were found within peripheral nerve fibers (cf Peters et al., 2006) . Initially, cutaneous nerves were classified as being either "afferent" controlling eccrine functions, blood flow and hair erection, or "efferent" transmitting sensory signals to the central nervous system (Peters et al., 2006) . This concept was challenged after the discovery of the first neuropeptide, substance P (SP), in sensory nerve fibers (Hokfelt et al., 1975) and it was soon suspected that SP and other sensory neuropeptides may have multiple bioactivities in the skin exceeding these classical functions. Subsequently, many trophic (Tanaka et al., 1988; Haegerstrand et al., 1989; Peters et al., 2006) and immunomodulatory (Hosoi et al., 1993; Black, 2002; Steinhoff et al., 2003; Peters et al., 2006) properties of nerve fiber and skin cell-derived neuropeptides have been reported (supporting Supplementary material) in health and disease. Therefore, the term "neuropeptides" is not strictly confined to peptide mediators derived from neurons, but is used for historical and didactical reason.
By expressing neuropeptides and neuropeptide receptors, nerves, resident skin cells and infiltrating migratory immunocytes share a powerful neuropeptide "language", which enables an interdependent communication between the central nervous system and the skin immune systems on multiple levels. This communication allows us to readily adapt to our environment but also contributes to disease when deregulated. In this review, we will discuss the latest scientific insights into neuropeptide signaling in skin and cutaneous disease pathology to improve the long missing appreciation of this molecule family in cutaneous biology. We will focus on the most common and best-studied neuropeptides SP, calcitonin gene-related peptide (CGRP), adrenomedullin (AM), vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide (VIP/PACAP), neuropeptide Y, or bradykinin (BK). This will provide the reader with sound pathomechanistic concepts and therapeutic strategies especially for patients with chronic and often frustrating to treat diseases such as atopic dermatitis, psoriasis, or cancerrelated issues.
Keratinocytes and fibroblasts are major targets of cutaneous neuropeptide signaling
The undecapeptide SP is a member of the tachykinin family and shares a precursor molecule with neurokinin A (Severini et al., 2002) . Cutaneous effects of tachykinins including SP are mediated via at least three different neurokinin receptors (NK 1 -NK 3 ) (Scholzen et al., 1998; Steinhoff et al., 2003) . Human and murine keratinocytes express functional NK 1 with high affinity for SP (Scholzen et al., 1998; Steinhoff et al., 2003; Peters et al., 2006) . NK 1 stimulation preferentially leads to a phospholipase C-mediated increase of early inositol 1,4,5-trisphosphate (IP 3 ) and a late increase of IP 1 . This is followed by intracellular Ca 2+ -mobilization, activation of protein kinase C, and nuclear factor-kappa B, without evident cross talk to cAMP/Protein kinase A signaling (Koizumi et al., 1992) .
Keratinocytes also express functional receptors for the neuropeptides PACAP and VIP, which belong to the VIP/secretin/glucagon family of peptides (Pozo, 2003) . Accordingly, VIP/PACAP receptors VPAC1 (also termed VIP1, VIP/PACAP type II, or PVR2) and VPAC2 (VIP2; VIP/PACAP type III; PVR3) bind VIP and PACAP with equal affinity (Kakurai et al., 2001; Kodali et al., 2004) .
Another important player, the 37 amino-acid neuropeptide CGRP is generated from the calcitonin gene RNA transcripts by alternative splicing. It is primarily located in nociceptive primary afferent cutaneous nerve fibers.
CGRP, which is encoded by a different, but closely related gene, differs from CGRP in three amino-acid positions and has overlapping biological actions (Brain and Grant, 2004) . CGRP signaling through specific receptors is slightly more complex compared to other neuropeptides. An orphan calcitonin receptor-like receptor is responsible for ligand binding, whereas receptor activity-modifying proteins define receptor specifity for CGRP or AM. Specific CGRP binding to the calcitonin receptor-like receptor requires receptor activity-modifying proteins 1, whereas association of calcitonin receptor-like receptor with receptor activitymodifying proteins 2 or 3 constitutes an AM 1 or AM 2 receptor phenotype, respectively (Foord and Marshall, 1999) . The expression of CGRP and AM receptor components has been demonstrated in human keratinocytes and skin fibroblasts, but a clear analysis of the differentiated action of CGRP and AM on these cells has yet to be performed (Albertin et al., 2003) . Both VIP and CGRP signaling in keratinocytes involve cAMP induction and Ca2+-mobilization (Haegerstrand et al., 1989; Takahashi et al., 1993) .
Remarkably, a property shared by many cutaneous neuropeptides appears to be their skin cell proliferation-promoting capacity. SP induces proliferation of murine and human keratinocytes (Tanaka et al., 1988; Scholzen et al., 1998) and dermal fibroblasts (Nilsson et al., 1985) . In addition, it promotes fibroblast migration in an NK 1 -dependent manner (Kahler et al., 1993) . Whereas VIP as well as CGRP either alone or in conjunction with SP stimulate proliferation of murine (Seike et al., 2002) and human keratinocytes (Takahashi et al., 1993; Kakurai et al., 2001) , the functional role of VIP and CGRP in skin fibroblasts is less defined. In contrast, neuropeptide Y apparently antagonizes cAMPinduced keratinocyte proliferation (Takahashi et al., 1993) , while by itself it has no effect on keratinocyte proliferation or apoptosis. Thus, since cutaneous innervation is required for wound contraction and scarless fetal wound healing in sheep (Stelnicki et al., 2000) , and the trophic net-effect of neuropeptides in keratinocyte and fibroblast biology appears to be proliferative, neuropeptides may be important players in wound healing, hyperproliferative skin disorders, and mesenchymal dysfunctions such as scleroderma (see also Supplementary material).
Neuropeptide containing innervation changes during trophic and inflammatory tissue remodeling in skin
Neuropeptide-containing nerves show striking plasticity during physiological and pathophysiological tissue remodeling processes Due to their keratinocyte proliferation-inducing capacities, neuropeptides were suspected to be important players in epithelial tissue homeostasis and remodeling of cutaneous tissue and skin appendages. This was confirmed initially by studies demonstrating that SP is required to maintain the structure of taste buds (Lundberg et al., 1979) . More recently, the plasticity of neuropeptide-containing nerve fibers during physiologically occurring tissue remodeling processes has been demonstrated in hair follicle development and cycling, a particularly well-suited model for studying the effects of neuropeptides on neuroectodermal-mesodermal interactions (cf Peters et al., 2006) . During cutaneous development, growth of SP and CGRP immunoreactive nerve fibers into the skin is strictly controlled in a time-, spatial-and function-dependent manner (cf Peters et al., 2006) . Initially, epidermal innervation is very dense, while it decreases and gains neuropeptide expression after penetration of hair follicles through the epidermis. This indicates a close association of skin appendage morphogenesis, innervation development, and sensory requirements (Peters et al., 2006) . While this remodeling process may be expected during morphogenesis, it continues into adulthood. Here, the number of neuropeptide containing nerve fibers increases during the early stages of hair growth (anagen development), decreases during hair follicle regression (catagen), and stays low in the resting stage (telogen) (Peters et al., 2001) as do their contacts with mast cells (Peters et al., 2006) . These changes are of functional relevance for hair growth since exogenous SP, but not VIP or CGRP promotes anagen progression in murine skin organ culture (Peters et al., 2001) and induces hair growth (anagen) in murine back skin. By contrast, high-dose SP induces dystrophic catagen in mice (Maurer et al., 1997) and cultured human anagen hair follicles (Peters et al., manuscript in preparation) . These studies were the first to demonstrate plasticity of neuropeptide containing nerve fibers during physiologically occurring tissue remodeling processes namely the hair cycle in the adult mammal.
In addition to this physiologically occurring plasticity of cutaneous innervation and neuro-immune interaction, neuronal plasticity in the skin of mice is also induced by environmental challenges such as the exposure to stress elicited by noise. Within 24 hours after noise exposure, the number of nerve fibers containing neuropeptides and their contacts to mast cells increase in murine back skin in comparison to the skin of animals not exposed to this inescapable stressor (cf Peters et al., 2006) . This stress-induced neuronal plasticity occurs in telogen as well as high anagen skin, where SP+ and CGRP+ nerve fiber numbers are normally low (Peters et al., 2001) . The untimely rise leads to a deleterious neurogenic inflammatory response as described below, with increased numbers of degranulating mast cells and infiltrating immunocytes such as macrophages (cf Peters et al., 2006) . The resulting net-effect leads to apoptosis of dermal cells and cells in the hair follicle stem cell region and the hair bulb in an NK 1 , nerve growth factor (NGF), and mast cell dependent manner. Ultimately, hair growth is prematurely terminated or arrested in telogen (for details, see Perspectives article by Arck et al., 2006) . Therefore, as demonstrated in the hair follicle as a model organ, rearrangement of the cutaneous sensory nervous system during tissue remodeling is a prerequisite for the skin to adapt to environmental changes such as temperature or noxious stimuli (see also Supplementary material) (Peters et al., 2006) . NK 1 -antagonists and NGF-neutralizing antibodies were efficiently implemented to neutralize negative stress effects on hair growth. This suggests that interference with neuropeptide signaling will prove an effective measure in the management of stress-associated hair loss and future studies of cutaneous remodeling and wound healing will benefit from this example.
Dermatitis alters cutaneous innervation
cutaneous innervation appears to be changed in a number of inflammatory skin diseases and disease models, including psoriasis, allergic dermatitis, and alopecia arreata (Pincelli et al., 1993; Hordinsky and Ericson, 1996; Steinhoff et al., 2003; Peters EMJ, Tobin DJ, Hagen E, Kuhlmei A, Knackstedt M, Peter AS et al. (2006) . Stress induced neurogenic inflammation exacerbates allergic dermatitis in mice. FASEB J, under review), though many of these reports are confusing. Especially in atopic dermatitis patients both increased and decreased numbers of neuropeptide containing nerve fibers have been reported in skin (cf Peters et al., under review) . This discrepancy may be due to the difficulty to acquire homogenous human skin samples. For example, environmental factors that are capable of modulating neuronal plasticity such as stress are usually not monitored in such studies.
However, under defined inflammatory conditions in the mouse, topical or intracutaneously applied antigens induce a long-lasting increase in nerve density and axonal growth of SP/CGRP-containing fibers as fast as 48 hours after induction of inflammation. This suggests that neuropeptides are involved in the disease development and maintenance (Huang et al., 2003; Peters et al., under review) . This pathogenetic knowledge can help to increase patient understanding of their symptoms and enhance their compliance during specific and often time-consuming therapeutic intervention.
Neuropeptides control cutaneous inert and specific immune responses
Neuropeptides control mast cell functions and orchestrate neurogenic inflammation SP and CGRP initialize neurogenic inflammation, a term coined to describe neurogenic mast cell degranulation with subsequent vascular responses (Steinhoff et al., 2003 ; Figure 1 ). The latter includes development of rapid erythema, edema, and increased permeability of mainly venules, which occurs directly via NK 1 -expressing endothelial cells, or indirectly via released mast cell products induced by SP (Steinhoff et al., 2003) (Figure 1 ). In addition, CGRP, but also AM induce long-lasting erythema, based on the vasodilatation of mainly arterioles (Brain and Grant, 2004) . Contributing neuropeptides also include VIP, which effectively dilates small blood vessels and like neuropeptide Y and CGRP stimulates mast cell degranulation and histamine-release (Wallengren, 1997). Once triggered, locally generated kinins further enhance neurogenic skin inflammation by additional release of SP, neurokinin A and CGRP from cutaneous afferent sensory neurons (Geppetti, 1993; Steinhoff et al., 2003) . Neuropeptides are key players in neurogenic inflammation. This schematic drawing depicts neurogenic inflammatory signaling pathways and up-and downstream regulatory and effector modules (modified from Steinhoff et al., 2003) . Along the brainskin axis, neuropeptides are involved in cutaneous inflammation on several levels including central transmission, neurogenic inflammation and cellular infiltration. SP and CGRP released from sensory nerve endings upon provocation mediate mast cell degranulation and regulate blood flow and plasma extravasation. Cytokines are recruited from keratinocytes and mast cells to initiate subsequent cutaneous infiltration. Positive feedback loops involving proteinase activated receptors on sensory nerve endings and neurotrophins that enhance innervation further promote this process. Degrading enzymes expressed, for example, by schwann cells and mast cells serve to terminate the process. Abbreviations: ATP -adenosinetrisphospate, CGRP -calcitonin gene-related peptide, CRH -corticotropin releasing hormone, DPP IV -dipeptidyl peptidase IV, ICAMintercellular adhesion molecule, IFN -interferon, IL-interleukin, NEP -neutral endopeptidase, NGF -nerve growth factor, PAR -proteinase activated receptor, SPsubstance P, TNF -tumor necrosis factor, UV -ultraviolet light, VCAM -vascular cell adhesion molecule.
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Apparently, virtually all neuropeptides synergize in maximizing cutaneous neurogenic inflammatory responses. Thus, an overall proinflammatory role has been proposed particularly for SP and CGRP due to their synergism in the initial and predominantly vascular part of the cutaneous immune response (Brain and Grant, 2004; Grant et al., 2005) . This may have important, as yet underestimated consequences for inflammatory skin diseases. However, in contrast, CGRP suppresses functions of dendritic cells (DCs) and T cells relevant for adaptive immunity (see below).
Neuropeptide induced release of cytokines from mast cells or keratinocytes initiates cellular infiltration
SP is capable of triggering the release of cytokines such as tumor necrosis factoralpha from mast cells in an NK 1 dependent manner (Ansel et al., 1993) . Keratinocyte derived IL-1 (Viac et al., 1996) may activate cutaneous as well as infiltrating cells and triggers the additional axonal transport and release of neuropeptides from sensory nerves (Jeanjean et al., 1995;  Figure 1 ). In addition, mast cell maturation factors such as IL-4 or stem cell growth factor increase the sensitivity of bone-marrow derived mast cells to SP by inducing mast cell NK 1 expression (van der Kleij et al., 2003) . Therefore, neuropeptides, mast cells, and cytokines form a triangle of paracrine activation. Subsequently, cytokines either alone or in conjunction with neuropeptides initiate cellular infiltration.
Neuropeptide-initialized hyperemia passively contributes to inflammatory cell recruitment by locally increasing cutaneous blood flow. Moreover, SP and neuropeptide Y stimulate endothelial cell proliferation (Steinhoff et al., 2003) and thus likely contribute to angiogenesis, neovascularization, and further increased influx of immune cells, particularly into chronically inflamed tissues. Beyond this indirect recruitment of inflammatory cells, SP increases adhesion of immunocytes to NK 1 -bearing microvascular endothelial cells by upregulating vascular and intercellular cell adhesion molecule 1 (Figure 1 ; Lindsey et al., 2000) . This directly promotes lymphocyte adhesion and extravasation, eosinophil infiltration, and eosinophil superoxide production (Lindsey et al., 2000; Foster and Cunningham, 2003) . SP is also capable of stimulating natural killer cell migration, activation, and cytotoxicity (Feistritzer et al., 2003) . CGRP additionally modulates leukocyte and macrophage infiltration and is chemoattractive for lymphocytes (Ansel et al., 1997) .
Selected neuropeptides affect antigen presentation and T-cell activation
Not only the skin but also primary and secondary lymphoid organs are densely innervated. Accordingly, in lymph nodes, afferent neuropeptide containing nerve fibers terminate in the area of high endothelial venules and in the T-cell zones (Steinman, 2004) . Therefore as discussed below, antigen presenting cells (APC) and T-cells infiltrating the skin are subject to stimulatory and inhibitory neuropeptide signaling in the skin as well as in lymphoid tissues (Figure 2) . Neuropeptides modulate DC-TC interaction. Stimulatory and inhibitory neuropeptide signaling holds APC-T-cell interaction in a balance (modified from Lambrecht, 2001). Antigen-presenting DCs receive neuropeptide signals from neuronal as well as non-neuronal sources. Similar to Toll-like receptors, TRPV family of receptors sense exogenous danger signals (capsaicin, heat, cold, pH-changes). BK and SP via BK B2 and NK1 receptors, respectively, constitute endogenous danger signals that initialize DC-dependent adaptive immune responses. DC maturation is accomplished by the nuclear factor-kappa B activation-dependent induction of proinflammatory cytokines (e.g., IL-12), adhesion (CD54), and costimulatory molecules (B7=CD80/86; CD40), and promotion of antigen-presentation ("MHC II"). Inhibitory non-neuronal (e.g., skin cell-derived -melanocyte stimulating hormone --MSH, via melanocortin 1 receptors -MC1) or neuronal peptides (calcitonin gene-related peptide -CGRP; vasoactive intestinal peptide -VIP; and potentially neurokinin A -NKA) deliver signals that directly and indirectly via cytokines (IL-10) impair DC functions including the expression of MHC II and costimulatory molecules. In addition, DC and T-cells (TC) produce auto-and/or paracrine-acting endogenous SP and CGRP. Neuropeptide signaling supplements cell-cell contact-dependent signals delivered by molecules constituting the immunologic synapse and drive T-cell helper phenotype, proliferation, cytotoxicity, and integrin expression. Neuropeptide bioactivity is controlled by the relative cellular presence of peptide receptors and peptide-degrading peptidases (NEP -neutral endopeptidase; ACE -angiotensin-converting enzyme) expressed on DC and T-cells. Despite their activating role in neurogenic inflammation and in contrast to SP, CGRP, and VIP/PACAP inhibit interaction at the DC-T-cell interface, Langerhans cell antigen presentation, and antigen-dependent T-cell activation (Hosoi et al., 1993; Kodali et al., 2004) . Langerhans cells express VIP/PACAP receptors, display CGRP surface binding, and an endogenous CGRP expression has been suggested (He et al., 2000) . In addition, T-cells also express CGRP and CGRP or VIP directly modulate T-cell function (Lambrecht, 2001) , which suggests the existence of autocrine or paracrine feedback loops. Generally, CGRP is considered to attenuate T-cell activity and to shift a TH 1 to a TH 2 cytokine profile via cAMP/PKA signaling (Seiffert and Granstein, 2002) .
In summary, as a net effect on DC/T-cell function, SP appears to boost APC functions, which may serve to avoid T-cell anergy (Lambrecht, 2001; Marriott and Bost, 2001) . By contrast, CGRP and VIP/PACAP inhibit APC functions (Figure 2 ). This suggests that these neuropeptides differentially fine-tune the DC-T-cell interface during initialization and establishment of adaptive immunity, although they act synergistically and overall proinflammatory in neurogenic inflammation and early phase cellular infiltration. Future studies have to determine, to which extent neuropeptides may interfere with signaling pathways induced by molecules constituting the DC-T-cell immunologic synapse.
Neuropeptide activity depends on enzymatic termination
Peptidases have long been recognized as key components of the neuropeptide system both as activators as well as terminators of neuropeptide activity. They serve to cleave bioactive peptide mediators from larger prohormone precursors to initialize inflammatory and trophic responses. More importantly though, a variety of ubiquitous neuropeptide-degrading enzymes such as neutral endopeptidase (NEP, neprilysin, CD10), angiotensin-converting enzyme (CD 143) or dipeptidyl peptidase IV (CD26) (see Supplementary material) rapidly terminate bioactivity of neuropeptides released from nerve terminals or endocrine cells. Thus, peptidase activity prevents the development of a neuropeptide-initialized deleterious chronic inflammation (Figure 1 ).
In addition, regulation of bioavailability by peptidases has been evolutionary important for immediate host defense, since a number of neuropeptides such as SP or AM have direct antimicrobial properties (Brogden et al., 2005) . Moreover, peptidases probably regulate trophic neuropeptide functions in tissue remodeling processes such as keratinocyte and melanocyte proliferation, hair cycle control, sebaceous gland function, and cutaneous wound healing (Black, 2002; Scholzen and Luger, 2004; Peters et al., 2006) . Not surprising, prolonged or chronic cutaneous inflammatory diseases are frequently accompanied by impaired expression and function of neuropeptide-degrading enzymes (Scholzen and Luger, 2004) . Given the TH 1 promoting capacities of neuropeptides such as SP, increased activity of degrading enzymes may specifically drive TH 2 dominated skin disease (Scholzen and Luger, 2004) . Therefore, regulated expression and activity of neuropeptide-degrading proteases is important for tissue homeostasis and control of cutaneous inert as well as adaptive immunity.
Neuropeptides differentially modulate immediate and delayed-type hypersensitivity reactions and thereby contribute to the development and maintenance of cutaneous inflammatory diseases
In various models of acute (Ahluwalia et al., 1998; Joachim et al., 2004; Grant et al., 2005; Peters et al., 2006) , but interestingly not chronic inflammation (Castagliuolo et al., 2002) , the lack of NK 1 protected mice from inflammatory damage. These models include dinitrofluorobenzene-induced allergic contact dermatitis as a model for type IV responses (Scholzen et al., 2004) and ovalbumine-induced allergic dermatitis as a model for atopic dermatitis-like combined type I and IV responses (Peters et al., under review).
In allergic contact dermatitis, mice lacking NK 1 display impaired neurogenic inflammation (Grant et al., 2005) and reduced IL-1 dependent neutrophilic infiltration (Ahluwalia et al., 1998) . In analogy to noise-stress, environmental factors such as low humidity and unpleasant odorant inhalation are stressors that regulate SP expression (Hosoi and Tsuchiya, 2000) and can also worsen allergic contact dermatitis (Hosoi and Tsuchiya, 2000) . In addition, knockout mice selectively lacking CGRP but not CGRP display reduced neurogenic inflammation (Grant et al., 2005) . In ovalbumine-induced allergic dermatitis, stress induced by noise-exposure modulates cutaneous innervation and nerve fiber mast cell contacts leading to excessive neurogenic inflammation. A cascade that exacerbates the dermatitis in an NK 1 -dependent manner (Peters et al., under review) .
By contrast, pleasant odorants may have relaxing properties, decrease SP-effects, and suppress allergic contact dermatitis via as yet not defined mechanism (Hosoi and Tsuchiya, 2000) . Moreover, CGRP induced selective tumor necrosis factor-alpha-release from mast cells effectively reduces cutaneous contact hypersensitivity (Seiffert and Granstein, 2002) . From these observations it becomes evident that SP via NK1 in conjunction with other neuropeptides and cytokines supports general proinflammatory mechanisms relevant for innate immunity such as neurogenic inflammation. This may explain exacerbation of acute cutaneous inflammatory diseases after environmental challenges and during stress. SP antagonists, CGRP agonists, and relaxation techniques may therefore proof useful measures in the management of cutaneous inflammatory diseases susceptible to neurogenic inflammation induced exacerbation (Peters et al., under review) . Yet, the undefined role of CGRP, related peptides, and their receptors requires attention by future studies.
However, the impact of SP/NK 1 on the DC-T-cell interface also helps to initialize adaptive immune responses in cutaneous pathology (Grant et al., 2005) . This hypothesis is further supported by the observation that NK 1 agonists promote murine antigen sensitization in allergic contact dermatitis and reverse neuropeptide-induced immunosuppression (Niizeki et al., 1999) . Consequently, pharmacologic inhibition or genetical knockout of NK 1 not only disrupts acute inflammatory responses such as neurogenic inflammation but also impairs antigen sensitization in vivo (Scholzen et al., 2004) . The latter could be mimicked by adoptive transfer of DCs treated in vitro with an NK 1 -antagonist indicating that SP via NK 1 affects intrinsic APC properties relevant for the initialization of adaptive immunity (Figure 2 ; Scholzen et al., 2004) . In addition to SP, B 2 agonists including BK not only induce DC maturation but also switch a TH 2 to a TH 1 immune response in a mouse model of allergic inflammation (Aliberti et al., 2003) . In line with these studies, pharmacologic B 2 inhibition before antigen sensitization impairs allergic contact dermatitis (Scholzen and Luger, 2004) .
In contrast to SP and BK, VIP, PACAP, and CGRP by modulating the DC-TC interface appear to counterbalance proinflammatory neuropeptides in vivo (Hosoi et al., 1993; Kodali et al., 2004) . Such examples demonstrate that the immunmodulatory functions of neuropeptides can be effectively and selectively utilized to develop therapeutic approaches for inflammatory diseases involving adaptive immunity.
Other neurocutaneous effects on antigen sensitization are likely more complex. DCs express a member of the transient receptor potential channel vanilloid (TRPV) subfamily, TRPV 1 , and activation of this receptor on immature DCs by capsaicin promotes DC maturation and migration into regional lymph nodes in vivo (Basu and Srivastava, 2005) . Although this could not be confirmed in a second study (O'Connell et al., 2005) , this leaves the fascinating possibility that DCs may respond to capsaicin even in the absence of cutaneous nerve fibers. This would imply that impaired cutaneous antigen sensitization and diminished contact hypersensitivity observed in capsaicin-denervated skin may involve a local downregulation of DC TRPV 1 expression (Basu and Srivastava, 2005) .
It is tempting to speculate that TRPV receptors and their "ligands" (heat, cold, or neuroactive agents such as capsaicin) similar to Toll-like receptors may sense important exogenous danger signals that directly promote APC function and initialize adaptive immunity independent from sensory nerves. Neuronal and non-neuronal tachykinins, kinins, and vanilloid-receptor ligands may therefore be viewed as natural endogenous adjuvants and danger-signals for key APC of the vertebrate immune system (Matzinger, 2002; Aliberti et al., 2003) .
Dysregulation of the self-regulatory pathways mentioned above leads to worsening of acute or the transition to chronic inflammatory skin diseases. The integration of the central position that neuro-immune interactions have in cutaneous disease will be a challenging task for researchers and clinicians alike in the future development of treatment options.
Neuropeptides in tumor development
CGRP, besides being involved in vasodilatation and pain, has been shown to be a tumorigenic factor in some cancers (Zhang et al., 2003) . Recently, in a mouse hind paw fibrosarcoma model for cancer pain, a close apposition of tumor cells and peripheral nerves was reported (Wacnik et al., 2005) . This suggested that tumor-produced mediators may chronically stimulate nerve fibers and both physical and biochemical interactions between nerves and tumor cells may contribute to cancer-associated pain (Figure 3a ; Wacnik et al., 2005) . Visual characterization of the actual interaction between nerves, tumor, and their environment revealed that the density of CGRP-immunoreactive pain afferents within the soft-tissue tumor mass is responsible for hyperalgesia in a CGRP receptor-dependent way (Wacnik et al., 2005) . In the pretreatment scalp, PGP-immunoreactive epidermal nerve fibers (ENFs) (green) are abundant in and Substance P (red) is sparse whereas after treatment, ENFs are almost entirely depleted. These laser scanning confocal images were captured at 20. Scale bar=100 m.
Full figure and legend (172K)Download Power Point slide (335 KB) Accordingly, the tumor grows alongside and among surrounding nerve fibers, without apparent nerve tissue destruction or derangement. Interestingly in some experimental systems, AM inhibited apoptosis, suggesting that AM may contribute to survival of damaged and/or premalignant cells (Albertin et al., 2003) . Moreover, a role of sensory fiber innervation in tumor proliferation has been suggested (Wacnik et al., 2005) . Perineural invasion is associated with increased aggressiveness and recurrence among cutaneous malignancies (Feasel et al., 2001 ) and may facilitate tumor metastasis. Fascinatingly in melanoma cells, reconstitution of dipeptidyl peptidase IV activity altered tumorigenicity (Wesley et al., 1999) , demonstrating the feasibility of neuropharmacotherapeutic intervention in tumor therapy. Some of these potential mechanisms may direct future investigations of interdependent actions of neurotrophic and tumorigenic factors released from tumor cells and nerves, respectively, that might participate in nociception, angiogenesis, and tumorigenesis.
Therapeutic options derived from intervention with neuropeptide signaling pathways: a future perspective
From the above it becomes apparent that neuropeptides shared by components of the endocrine, the skin immune as well as the peripheral and central nervous system are released from neuronal and non-neuronal sources including the skin. They feed into a complex network of interacting mediators that modulate inflammation and growth control. Neuropeptide signaling is controlled at the level of release, receptor expression, and by proteolytic peptidases. Unbalanced pro-and anti-inflammatory neuropeptides (e.g., after exogenous stressors) deregulate cutaneous homeostasis and trigger or exacerbate cutaneous diseases such as atopic dermatitis, allergic inflammation or psoriasis. Since neuropeptides could be regarded as endogenous and therefore "natural" therapeutics that are small and capable of penetrating the epidermal barrier, the use of modified peptides as therapeutic agonist or antagonist for the treatment of cutaneous disorders appears attractive. However, the functional complexity of neuropeptide signaling requires balancing of activating and inhibitory functions (Figure 4 ) and objective definition of time point, combination, and dosage of intervention. Nonetheless, some therapeutic strategies derived from our present understanding of the topic are outlined below and may be regarded as guidance for future investigations. Neuropeptide circuits in the control of tissue maintenance and inflammation. Activating and inhibitory neuropeptide functions together with regulatory proteases keep the central stress-response, the peripheral cytokine production, and the local neurogenic inflammatory response in a balance. Many neuropeptides hereby act in a dual fashion depending on the target and signaling context. SP, BK, CGRP, and VIP/PACAP, for example, all activate mast cells in the process of neurogenic skin inflammation. By contrast, SP inhibits HPA-axis activation and CGRP and VIP/PACAP inhibit DC activation. Where these circuits are broken, for example, by an overflow of stimulatory triggers disease is facilitated.
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Drug delivery: smaller is better
Regulatory peptides are an intriguing, as yet underestimated target for pharmacological intervention. Breakthroughs in nano-technology have enabled the production of topical formulations that can cross the stratum corneum and thus promise to multiply the yield of testable drug candidates from the discovery process (Connors and Elder, 2004) . Preclinical data support the development of formulations that either deplete nerve fibers, or contain antagonists against receptors for neuropeptides, cannabinoids, vanilloids, cytokines, BK, adenosine, ATP, or biogenic amines. Pharmacologic targets may as well be NGF and neuropeptide-activating or -degrading peptidases. Given that activity of sensory neurons involves multiple mediators, combinations of agents targeting different mechanisms may be particularly useful. In addition to pharmacological intervention, however, psychosocial intervention and relaxation techniques also offer promising real, immediately available therapeutic options for stress-aggravated skin diseases (Hosoi and Tsuchiya, 2000; Black, 2002; Joachim et al., 2004) .
Capsaicin and other naturally occurring compounds
The neurotoxin capsaicin depletes sensory nerves from neuropeptides and activates TRPVs, particularly TRPV 1 (Steinhoff et al., 2003) . TRP ion channels are promising targets for the treatment of itch. Topical application of capsaicin (0.075%) to deplete SP from cutaneous nerve terminals also activates the TRPV 1 and alters follicular innervation (Figure 3b ). The initial burning pain and hyperalgesia pose a challenging task in the initial management of patient compliance. Once this is overcome, however, the extended treatment with topical capsaicin leads to a dose-dependent, partially reversible (Simone et al., 1998) loss of epidermal C-fibers, which may relieve localized chronic itch (Figure 3b ) without major side effects such as histamine-release or local edema (Steinhoff et al., 2003) . By contrast, menthol activates the cold-sensitive TRPM8 and the resulting cooling perception can relieve the itch perception as well. The potential of new topical formulations containing natural compounds such as cinnamon oil, wintergreen oil, clove oil, mustard oil, and ginger that all activate TRPA1 may hold great promise.
UV-light triggers neuropeptide-release
There is evidence that UV exposure of skin reduces endothelial NK 1 -expression (Staniek et al., 1998) , induces epidermal hyperinnervation and triggers SP and CGRPrelease from sensory nerves (Scholzen et al., 1999) . In addition, UV-induced CGRPrelease triggers tumor necrosis factor-alpha-release from mast cells (Seiffert and Granstein, 2002) and upregulates NEP expression in melanocytes and endothelial cells (Scholzen and Luger, 2004) . In the wake of these events, UV-released neuropeptides may first add to UV-induced acute inflammation but ultimately induce immunosuppression via the above-described pathways. This response is possibly under the control of NGF (Scholzen et al., 1999; Seiffert and Granstein, 2002) . The widely used anti-inflammatory effects of UV-light may therefore be contributed at least in part to UVtriggered neuropeptide-release as this evidently reduces, for example, cutaneous contact hypersensitivity responses (Seiffert and Granstein, 2002) . Likewise, UV-induced proteases by reducing SP bioactivity may be beneficial for hyperproliferative skin diseases such as psoriasis, which is characterized by an increased immunoreactivity of SP-positive nerve fibers (Chan et al., 1997) .
Neurokinin antagonists
As SP via NK 1 acts both proinflammatory and immune-stimulatory, NK 1 receptors are attractive pharmacologic targets to neutralize neurogenic inflammation. In modern clinical praxis, they serve as an important adjuvant strategy for the management of skin diseases such as atopic dermatitis, psoriasis or allergic contact dermatitis (Scholzen et al., 1998; Niizeki et al., 1999; Steinhoff et al., 2003) . NK 1 antagonist treatment is suited to reduce "danger-signaling" in the skin and thereby attenuate stress-induced aggravation of cutaneous inflammation T-cell mediated skin diseases as discussed above. NK 1 antagonists have passed clinical trials and are now available for treatment of anxiety, nausea, and depression as well as pain (Steinhoff et al., 2003) and NK 1 antagonist can be successfully delivered into the skin (Kikwai et al., 2004) .
CGRP-receptor antagonists
CGRP and associated molecules are powerful tools to suppress antigen presentation, and may therefore find a place in the treatment of allergic and autoimmune skin diseases. Accordingly, novel non-peptide CGRP receptor antagonists such as BIBN4096BS, which are currently on trials for the treatment of migraine, appear to attenuate CGRP and AM-induced cutaneous microvascular responses. Future clinical dermatological research should therefore employ these antagonist alone ore in combination with neurokinin antagonists to neutralize neurogenic inflammation (Brain and Grant, 2004; Grant et al., 2005) or to attenuate CGRP-mediated tumor-induced hyperalgesia (Wacnik et al., 2005) .
Neuropeptide degrading enzymes
Regulation of neuropeptide-degrading enzymes may have a powerful impact on the outcome of cutaneous inflammatory responses. A downregulation of endogenous proteases was observed in response to microbial infection (Rempel and Pulliam, 2005) , which might aid to initialize the inflammatory response and to maintain accessibility of cells to cell-survival ensuring growth factors (Scholzen and Luger, 2004) . Thus, targeting neuropeptide-degrading enzymes could be a therapeutic strategy for the treatment of inflammatory skin disease. However, increased NEP expression during lymphocyte maturation either marks immature cells or cells sentenced to apoptotic cell death (Scholzen and Luger, 2004) . Moreover, since enhanced neuropeptide degradation may interfere with host defense, fine-tuning of this interventional strategy will be challenging.
Neuroimmunophilin ligands
Topical neuroimmunophilin ligand FK506 is widely appreciated in the therapy of chronic cutaneous inflammatory diseases, particularly of atopic dermatitis. Interestingly, besides its well-known immunmodulatory functions relying on calcineurin inhibition, FK506 also stabilizes cutaneous innervation and mast cells, and is capable of decreasing the number of nerve fiber-mast cell contacts in atopic dermatitis skin. The antiinflammatory effects of immunophilin ligands may thus in part derive from their neuroprotective capacities. This is further supported by the observation, that FK506 as well as topically applied neuroimmunophilin ligand analogs (GPI1046 and GPI1511; Guilford Pharmaceuticals, Baltimore, MD), that lack its immunosuppressant activity, induce hair growth in mice. This suggests that the neuro-protective component of immunophillin ligand signaling plays a dominant role in cutaneous tissue remodeling processes as occurring during hair growth and potentially in neurogenic inflammation.
Perspectives
The complexity of cutaneous neuropeptide signaling does not allow a plain summary of key functions. It rather opens a cosmos of interdependent signaling pathways characterized by antagonistic functions such as activation versus suppression of immune responses (Figure 4) . However, below the bottom line, we find activation of acute inert and adaptive immune responses, whereas continuing immune responses are suppressed. Both features are key elements of cutaneous tissue remodeling processes such as the hair cycle or allergic cutaneous diseases such as atopic dermatitis. The nonpharmaceutical and pharmaceutical tools available today already provide us with a rich toolbox for future scientific and clinical efforts and should become basic dermatological knowledge.
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